AIkido Pharma Executes Licensing Agreement with University of Maryland for Antiviral Compounds, Including CoVID-19
New York, NY – April 21, – AIkido Pharma Inc. (NASDAQ: AIKI) (“AIkido” or the “Company”) today announced that on April 13, 2020, the Company executed a Master License Agreement (the “License Agreement”) with the University of Maryland, Baltimore (“UMB”). The License Agreement covers specific antiviral compounds discovered by UMB. The compounds seek to inhibit replication […]
AIkido Pharma Executes Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus
New York, NY – April 14, 2020 – AIkido Pharma Incorporated (Nasdaq: AIKI) today announced that it has secured an exclusive world-wide license for a broad spectrum antiviral drug platform. The licensed technology is a broadly acting pan-viral inhibitory compound with efficacy against multiple viral pathogens. The technology works to inhibit replication of multiple viruses […]
